Equities
Health CarePharmaceuticals & Biotechnology
  • Price (USD)8.70
  • Today's Change0.56 / 6.88%
  • Shares traded18.56m
  • 1 Year change-62.04%
  • Beta0.7357
Data delayed at least 15 minutes, as of Aug 16 2017 21:00 BST.
More ▼

Forecasts data is unavailable for this security.

Consensus recommendation

As of Aug 11, 2017, the consensus forecast amongst 22 polled investment analysts covering Endo International PLC advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Jun 09, 2017. The previous consensus forecast advised that Endo International PLC would outperform the market.
  • 1yr ago
  • 3M ago
  • 2M ago
  • 1M ago
  • Latest
Select bar for recommendation details.
RecommendationsLatest
Buy2
Outperform4
Hold14
Underperform0
Sell1

Share price forecast

The 16 analysts offering 12 month price targets for Endo International PLC have a median target of 12.50, with a high estimate of 19.00 and a low estimate of 8.00. The median estimate represents a 43.68% increase from the last price of 8.70.
High118.4%19.00
Med43.7%12.50
Low-8.0%8.00

Earnings history & estimates

On Aug 08, 2017, Endo International PLC reported 2nd quarter 2017 earnings of 0.93 per share. This result exceeded the 0.73 consensus of the 19 analysts covering the company and exceeded last year's 2nd quarter results by 8.14%.
The next earnings announcement is expected on Nov 06, 2017.
Average growth rate+9.45%
Endo International PLC reported annual 2016 earnings of 4.73 per share on Feb 28, 2017.
Average growth rate-1.12%
More ▼

Revenue history & estimates

Endo International plc had 2nd quarter 2017 revenues of 875.73m. This bettered the 836.41m consensus of the 16 analysts covering the company. This was 4.90% below the prior year's 2nd quarter results.
Average growth rate+1.10%
Endo International plc had revenues for the full year 2016 of 4.01bn. This was 22.69% above the prior year's results.
Average growth rate+8.17%
More ▼
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.